ICC Makes Strategic Investment in Disruptive Biosynthesis Research
April 16th, 2019
Exclusive, News, Top News
Biosynthesis is the process of manipulating simple substances to produce the complex molecules found within living organisms. Biosynthetic engineering, as applied to cannabis, means single cell organisms are programmed to synthesize the enzymes for the metabolic pathway that generates cannabinoids from sugars – promising new technology with the potential to shake up the nascent cannabis industry.
Guided by an understanding of the potential the technology offers, International Cannabis Corp. (CSE: WRLD.U)(FWB: 8K51)(OTC: WLDCF) announced on April 8th a USD $1.2 million strategic investment in Biotii Technologies Corp. a leading private biotechnology company actively pursuing genetically engineered microorganisms that express cannabinoid profiles identical to those found in nature – at a fraction of the cost of current production methods with more consistent quality and a greatly reduced carbon footprint.
Recent advancements in the areas of gene editing, in-silico protein modeling, and semi-automated high throughput robotics has enabled Biotii to expedite its molecular biology research, allowing the company to spearhead into large-scale production with a wide portfolio of intellectual property. This evolving portfolio is expected to consist of synthetic cannabinoids, designer enzymes, proprietary enzyme pathways, and GMO microorganisms.
Traditional cultivation of cannabis plants for the purpose of extracting cannabidiolic acid (CBDA), THC and CBD is a time, labour, and resource intensive endeavor which often results in lower yields. By 2020, the Biotii team plans to establish processes to mass-produce CBD/THC in quantities of hundreds of metric tons per annum boasting stable and consistent yields, pharmaceutical grade purities, and the lowest production costs in the cannabis space.
Commenting on the investment, Eugene Beukman, Chief Executive Officer and a Director of International Cannabis, said, “We are thoroughly impressed with the Biotii team, which consists of proven innovators from world-class institutions, whom we believe are en route to potentially disrupt a very large part of the cannabis value chain. ICC will continue to support Biotii’s distinguished team in their pursuit to bring economies of scale using biosynthesis to the cannabis industry. This investment enhances ICC’s ability to capture significant IP and market share in the fast-developing biosynthesis market for cannabinoids.”
In areas with more established cannabis markets, extract-based products have proven to be just as popular, and often more so, than the smoking of flower. Most consumers are new to cannabis and increasingly health conscious, so they’re much more likely to purchase derivatives and consumables. The development of biosynthetic cannabinoids could potentially eliminate the need for companies producing these products to invest in cultivation and processing, substantially lowering input costs and increasing revenues, while also cutting the industry’s overall ecological footprint.
Industry Investment Enabling Research
Cronos is working with synthetic biology firm Ginkgo Bioworks in an effort to develop a scalable system for producing synthetic cannabinoids, and if certain benchmarks are achieved, the deal could be worth USD $100 million in cash and stock incentives. This would give Cronos the exclusive right to commercialize key patented intellectual property related to the target cannabinoids in perpetuity. These include THC and CBD, but also lesser-known compounds also produced by the cannabis plant, which are of particular importance to pharmaceutical companies.
Tilray is working with IntelGenX Corp. to develop oral film products infused with synthetic cannabis for both recreational and medicinal use, citing a need for the greater consistency synthetics offer, especially for medical cannabis patients, as well as being free of the contaminants sometimes present in naturally-sourced cannabinoids.
The US Food & Drug Administration has been slow to approve synthetic cannabinoids, but since 2016, has started to liberalize its approach, a key step in advancing research.
ICC’s strategic investment with Biotii grants International Cannabis a right of first refusal with respect to all future Biotii financing.
Biotii Guided by a Winning Team
Dr. John Harrold, Biotii’s Chief Executive Officer, said, “Biotii looks forward to progressing our technology alongside ICC and their robust cannabis platform. ICC has earned a reputation of being a thought leader in the space and we are excited by the possibilities of tapping into ICC’s unique expertise and resources as we look to disrupt the cannabis industry.”
Dr. Harrold is an MIT instructor with expertise in end-to-end bio-lab management, and a proven entrepreneur, having previously championed four start-ups, including two funded by the National Science Foundation. Biotii has forged mission critical relationships with leading medical research institutions in both the United States and China.
Sisi Ni, Biotii’s Chief Product Officer, is an MIT trained materials scientist and engineer who was previously named as one of Forbes’ 30 under 30. Casey Solomon, PhD, the company’s Chief Science Officer/Lead Scientist, is a resident expert in yeast engineering, E. coli engineering, and molecular pathway engineering. Biotii’s Chief Medical Officer is Ryan Hubbard, MD, a former instructor at Mayo Clinic Graduate School of Medicine with over 25 publications, posters, and oral presentations.
Nona Tian, PhD is the company’s Science Advisor/Affiliated Researcher, a Xiamen University PhD graduate in Cell and Molecular Biology with a B.S. in biotechnology as well as a successful startup co-founder with extensive bioengineering experience. Peter Liu, Biotii’s Technology Advisor/Affiliated Researcher also graduated from Xiamen University with a B.S. in biotechnology, and is a seasoned protein engineer and startup co-founder that received various grants from the Chinese Government for bioengineering initiatives.
If the biosynthesis of cannabinoids proves to be a scalable technology, many of the companies involved in the production and sale of extract-based products could switch from traditional cultivation and processing to achieve their supplies in this alternative form, which would leave those with the foresight to invest in the technology now in a position to capitalize. Investors would do well to keep an eye on biosynthesis research and the companies like ICC who are making important moves now.
For more information, watch this page or visit https://intlcannabiscorp.com/news/
The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.